Jenkem Technology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary, Public
- Established
- 2001-10-09
- Employees
- 298
- Market Cap
- -
- Website
- http://www.jenkem.com
Clinical Trials
5
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (40.0%)Phase 2
2 (40.0%)Phase 3
1 (20.0%)JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase 2
Recruiting
- Conditions
- Glioblastoma Multiforme (GBM)
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- JenKem Technology Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT06595186
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer (TNBC)Brain Metastasases
- Interventions
- First Posted Date
- 2024-09-06
- Last Posted Date
- 2024-09-06
- Lead Sponsor
- JenKem Technology Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT06586866
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- JenKem Technology Co., Ltd.
- Target Recruit Count
- 394
- Registration Number
- NCT06581380
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- JenKem Technology Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT05158491
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan in Patients With Malignant Solid Tumor
Phase 1
Completed
- Conditions
- Solid Tumor
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- JenKem Technology Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04366648
News
No news found